Search EFSA Journal
Refine your search
Type
All article types
Special Issue Item
Journal Editorial
Scientific opinions of Scientific/Scientific Panel
Opinion of the Scientific Committee/Scientific Panel
Statement of the Scientific Committee/Scientific Panel
Guidance of the Scientific Committee/Scientific Panel
Other scientific outputs of EFSA
Statement of EFSA
Guidance of EFSA
Conclusion on pesticides
Reasoned opinion on pesticide
Scientific report of EFSA
Technical Report
Subject
All subjects
Animal health & welfare
Biological hazards
Biological monitoring
Contaminants
Dietary & chemical monitoring
Emerging risks
Feed
Food Ingredients and Packaging
GMO
Nutrition
Pesticides
Plant health
Assessment and methodological support
Scientific Committee
Scientific cooperation
Article ID
Digital Object ID
Sort by:
Publication date
Relevance

Scientific Opinion on the substantiation of a health claim related to ethanol-water extract of Caralluma fimbriata (Slimaluma®) and helps to control hunger/appetite pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Journal 2010; 8(5):1606 [10 pp.]. doi:10.2903/j.efsa.2010.1606
  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) Panel Members Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen Acknowledgment The Panel wishes to thank Joanne A. Harrold and the members of the Working Group on Claims for the preparatory work on this opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen Contact nda@efsa.europa.eu
Type: Opinion of the Scientific Committee/Scientific Panel On request from: Gencor Pacific Inc. Question number: EFSA-Q-2010-00031 Adopted: 30 April 2010 Published: 12 May 2010 Affiliation: European Food Safety Authority (EFSA), Parma, Italy
Abstract

Following an application from Gencor Pacific Inc. submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to ethanol-water extract of Caralluma fimbriata (Slimaluma®) and “helps to control hunger/appetite”. Slimaluma® is an ethanol-water extract of Caralluma fimbriata standardised by its content in pregnane glycosides that is sufficiently characterised. A reduction of appetite leading to a reduction in subsequent energy intake might be beneficial physiological effect. A double blind, placebo controlled, randomised trial in humans investigating the effects of Slimaluma® on appetite ratings and subsequent energy intake was considered as being pertinent to the claim. The mean hunger level of the experimental group was found to be significantly lower than that of the placebo group. No statistically significant differences in energy intake between the experimental and placebo groups were reported. The Panel concludes that a cause and effect relationship has not been established between the consumption of the ethanol-water extract of Caralluma fimbriata Slimaluma® and a reduction of appetite leading to a reduction in subsequent energy intake.

© European Food Safety Authority, 2010

Summary

Following an application from Gencor Pacific Inc. submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to ethanol-water extract of Caralluma fimbriata (Slimaluma®) and “helps to control hunger/appetite”.

The scope of the application was proposed to fall under a health claim based on newly developed scientific evidence.

The food constituent that is the subject of the health claim is an ethanol-water extract of Caralluma fimbriata (Slimaluma®). The ethanol-water extract of the aerial parts of Caralluma fimbriata is the source of the ingredients in Slimaluma® claimed as “active” by the applicant. The specific extraction and subsequent manufacturing processes are specified for the content of pregnane glycosides (at least 25 % by weight), which are claimed by the applicant to be the active ingredients for appetite control, of saponin glycosides (at least 10 by weight) and of bitters (at least 3 % by weight). The Panel considers that the food constituent, ethanol-water extract of Caralluma fimbriata (Slimaluma®), which is the subject of the health claim, is sufficiently characterised.

The claimed effect is “helps to control hunger/appetite”. The target population is overweight adults (i.e., > 18 years of age). The Panel considers that a reduction of appetite leading to a reduction in subsequent energy intake might be a beneficial physiological effect.

Ten publications were identified by the applicant as being pertinent to the claim. The references provided included in vitro studies, intervention studies and reviews on the reliability and validity of Visual Analogue Scales for the assessment of appetite, the central control of body weight and appetite, the link between leptin and obesity, the impact of soluble fibres or multivitamin and mineral supplements on body weight and mitotic clonal expansion. The Panel considers that no conclusions can be drawn from these references for the substantiation of the claimed effect.

Only one of the human intervention studies reported on measures of appetite and as such was considered pertinent to the claim. It was a double blind, placebo controlled, randomised intervention in 62 healthy overweight and obese volunteers. The experimental group received 1 g of ethanol-water extract of Caralluma fimbriata per day for 60 days whilst the placebo group received maltodextrin capsules. At baseline and at the end of 30 and 60 days of intervention assessment of appetite was performed in the fasted state using four visual analogue scales for ‘hunger’, ‘thoughts of food’, ‘urge to eat’ and ‘fullness of stomach’. At baseline and following 60 days of intervention, dietary intake was also assessed using a modified food frequency questionnaire. At day 60 only, the mean hunger level of the experimental group was found to be significantly lower than that of the placebo group. There were no significant differences reported for the other assessments of appetite over time within groups from baseline, or between the two groups. No differences in energy intake between the experimental and placebo groups were reported at day 60. The Panel notes that measurement of energy intake was via self-reported methods (rather than being measured directly within the laboratory), the validity of which is questionable.

The Panel considers that the results from the animal study and the one in vitro study do not predict an effect of the ethanol-water extract of Caralluma fimbriata Slimaluma® on the reduction of appetite in humans.

In weighing the evidence, the Panel took into account that whilst the ratings of hunger were significantly reduced in the experimental group compared to placebo at day 60 in the one human study presented which assessed this outcome, no significant effect of the ethanol-water extract of Caralluma fimbriata on energy intake was observed when compared to a suitable control.

The Panel concludes that a cause and effect relationship has not been established between the consumption of the ethanol-water extract of Caralluma fimbriata Slimaluma® and a reduction of appetite leading to a reduction in subsequent energy intake.

Keywords

Slimaluma®, Caralluma fimbriata, pregnane glycosides, hunger, appetite, energy intake, health claims